Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma

Tatsuhiro Shibata, Satoko Hanada, Akiko Kokubu, Yoshihiro Matsuno, Hisao Asamura, Tsutomu Ohta, Michiie Sakamoto, Setsuo Hirohashi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We examined the genome-wide expression profiles of 86 primary lung adenocarcinomas and compared them with the mutation status of the four key molecules (EGFR, ERBB2, KRAS and BRAF) in the EGFR/KRAS/BRAF pathway. Unsupervised classification revealed two subtypes (the bronchial type and the alveolar type) of lung adenocarcinoma. Mutually exclusive somatic mutations of the epidermal growth factor receptor (EGFR) gene (36/86, 41.8%), K-ras gene (11/86, 12.8%) and BRAF gene (1/86, 1.1%) were detected. KRAS mutations were observed significantly frequently in bronchial-type tumors, whereas the frequencies of EGFR mutations were similar in both the alveolar and bronchial types. Twenty-seven genes showed increased expression in EGFR-mutated tumors and these included molecules that function in the EGFR/KRAS/BRAF pathway (EGFR, AKT1 and BCR). In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer. A subgroup of the alveolar type tumors showed significantly better prognosis than other tumors. Integrated analysis of genetic and gene expression profiling aimed to delineate inherent oncogenic pathways in cancer will be valuable not only for the understanding of molecular pathogenesis, but also for discovering novel biomarkers and predicting clinical outcome.

Original languageEnglish
Pages (from-to)985-991
Number of pages7
JournalCancer Science
Volume98
Issue number7
DOIs
Publication statusPublished - 2007 Jul

Fingerprint

Gene Expression Profiling
Epidermal Growth Factor Receptor
Mutation
Neoplasms
Bronchiolo-Alveolar Adenocarcinoma
erbB-1 Genes
ras Genes
Adenocarcinoma of lung
Epidermal Growth Factor
Proteolysis
Genes
Lung Neoplasms
Biomarkers
Genome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. / Shibata, Tatsuhiro; Hanada, Satoko; Kokubu, Akiko; Matsuno, Yoshihiro; Asamura, Hisao; Ohta, Tsutomu; Sakamoto, Michiie; Hirohashi, Setsuo.

In: Cancer Science, Vol. 98, No. 7, 07.2007, p. 985-991.

Research output: Contribution to journalArticle

Shibata, Tatsuhiro ; Hanada, Satoko ; Kokubu, Akiko ; Matsuno, Yoshihiro ; Asamura, Hisao ; Ohta, Tsutomu ; Sakamoto, Michiie ; Hirohashi, Setsuo. / Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. In: Cancer Science. 2007 ; Vol. 98, No. 7. pp. 985-991.
@article{b0200e84d58e49219fedbce5b037600c,
title = "Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma",
abstract = "We examined the genome-wide expression profiles of 86 primary lung adenocarcinomas and compared them with the mutation status of the four key molecules (EGFR, ERBB2, KRAS and BRAF) in the EGFR/KRAS/BRAF pathway. Unsupervised classification revealed two subtypes (the bronchial type and the alveolar type) of lung adenocarcinoma. Mutually exclusive somatic mutations of the epidermal growth factor receptor (EGFR) gene (36/86, 41.8{\%}), K-ras gene (11/86, 12.8{\%}) and BRAF gene (1/86, 1.1{\%}) were detected. KRAS mutations were observed significantly frequently in bronchial-type tumors, whereas the frequencies of EGFR mutations were similar in both the alveolar and bronchial types. Twenty-seven genes showed increased expression in EGFR-mutated tumors and these included molecules that function in the EGFR/KRAS/BRAF pathway (EGFR, AKT1 and BCR). In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer. A subgroup of the alveolar type tumors showed significantly better prognosis than other tumors. Integrated analysis of genetic and gene expression profiling aimed to delineate inherent oncogenic pathways in cancer will be valuable not only for the understanding of molecular pathogenesis, but also for discovering novel biomarkers and predicting clinical outcome.",
author = "Tatsuhiro Shibata and Satoko Hanada and Akiko Kokubu and Yoshihiro Matsuno and Hisao Asamura and Tsutomu Ohta and Michiie Sakamoto and Setsuo Hirohashi",
year = "2007",
month = "7",
doi = "10.1111/j.1349-7006.2007.00483.x",
language = "English",
volume = "98",
pages = "985--991",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma

AU - Shibata, Tatsuhiro

AU - Hanada, Satoko

AU - Kokubu, Akiko

AU - Matsuno, Yoshihiro

AU - Asamura, Hisao

AU - Ohta, Tsutomu

AU - Sakamoto, Michiie

AU - Hirohashi, Setsuo

PY - 2007/7

Y1 - 2007/7

N2 - We examined the genome-wide expression profiles of 86 primary lung adenocarcinomas and compared them with the mutation status of the four key molecules (EGFR, ERBB2, KRAS and BRAF) in the EGFR/KRAS/BRAF pathway. Unsupervised classification revealed two subtypes (the bronchial type and the alveolar type) of lung adenocarcinoma. Mutually exclusive somatic mutations of the epidermal growth factor receptor (EGFR) gene (36/86, 41.8%), K-ras gene (11/86, 12.8%) and BRAF gene (1/86, 1.1%) were detected. KRAS mutations were observed significantly frequently in bronchial-type tumors, whereas the frequencies of EGFR mutations were similar in both the alveolar and bronchial types. Twenty-seven genes showed increased expression in EGFR-mutated tumors and these included molecules that function in the EGFR/KRAS/BRAF pathway (EGFR, AKT1 and BCR). In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer. A subgroup of the alveolar type tumors showed significantly better prognosis than other tumors. Integrated analysis of genetic and gene expression profiling aimed to delineate inherent oncogenic pathways in cancer will be valuable not only for the understanding of molecular pathogenesis, but also for discovering novel biomarkers and predicting clinical outcome.

AB - We examined the genome-wide expression profiles of 86 primary lung adenocarcinomas and compared them with the mutation status of the four key molecules (EGFR, ERBB2, KRAS and BRAF) in the EGFR/KRAS/BRAF pathway. Unsupervised classification revealed two subtypes (the bronchial type and the alveolar type) of lung adenocarcinoma. Mutually exclusive somatic mutations of the epidermal growth factor receptor (EGFR) gene (36/86, 41.8%), K-ras gene (11/86, 12.8%) and BRAF gene (1/86, 1.1%) were detected. KRAS mutations were observed significantly frequently in bronchial-type tumors, whereas the frequencies of EGFR mutations were similar in both the alveolar and bronchial types. Twenty-seven genes showed increased expression in EGFR-mutated tumors and these included molecules that function in the EGFR/KRAS/BRAF pathway (EGFR, AKT1 and BCR). In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer. A subgroup of the alveolar type tumors showed significantly better prognosis than other tumors. Integrated analysis of genetic and gene expression profiling aimed to delineate inherent oncogenic pathways in cancer will be valuable not only for the understanding of molecular pathogenesis, but also for discovering novel biomarkers and predicting clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=34249888222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249888222&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00483.x

DO - 10.1111/j.1349-7006.2007.00483.x

M3 - Article

C2 - 17459062

AN - SCOPUS:34249888222

VL - 98

SP - 985

EP - 991

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -